| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
MART-1 (26-35) targets the T-cell receptor (TCR) of MART-1-specific CD8+ cytotoxic T lymphocytes when presented by the MHC class I molecule HLA-A*0201. This peptide epitope (sequence: EAAGIGILTV) is recognized by tumor-reactive T cells in HLA-A2-positive melanoma patients.
|
|---|---|
| ln Vitro |
The MART-1 (Melan-A) gene has five exons and a length of 18 kb. Only melanocytes among normal cells express it, compared to most melanoma tumor samples [1]. Clinical vaccines based on MART-1/Melan-A protein variations and epitopes are commonly employed in cancer immunotherapy. A good example of T cell identification of numerous peptides and the usage of peptide variations intended to elicit altered immunological responses are the epitopes spanning amino acid residues 26–35 and 27–35 from the MART-1/Melan-A protein, which is widely expressed in melanoma cells [2].
The peptide is used to stimulate MART-1-specific CD8+ T cells in vitro. MART-1 is expressed in most melanoma tumor samples and, among normal cells, only in melanocytes of the skin and retina. This peptide demonstrates superior recognition by polyclonal and monoclonal populations of tumor-reactive HLA-A*0201-restricted CTLs compared to MART-1 (27-35). |
| ln Vivo |
Not available. MART-1 (26-35) peptide is used as a cancer vaccine antigen in preclinical melanoma models. In vivo immunization with this peptide in HLA-A2 transgenic mice induces antigen-specific CTL responses and has been studied for tumor immunotherapy applications, though no quantitative efficacy data are provided.
|
| Enzyme Assay |
Not available. For TCR binding assays, standard protocols involve loading HLA-A*0201 molecules with MART-1 (26-35) peptide (1-100 uM) by incubating for 2-4 hours at room temperature, forming peptide-MHC tetramers, and then staining T cells from melanoma patients to detect MART-1-specific CTLs by flow cytometry.
|
| Cell Assay |
For T-cell activation assays, typical protocols involve pulsing T2 cells or autologous dendritic cells with MART-1 (26-35) peptide (1-50 ug/mL) for 2-4 hours, washing, co-culturing with CD8+ T cells from HLA-A2-positive donors (10:1 effector-to-target ratio) for 5-7 days, and measuring IFN-gamma production by ELISA or ELISpot.
|
| Animal Protocol |
For in vivo immunotherapy studies, standard protocols involve emulsifying MART-1 (26-35) peptide (50-200 ug/mouse) in adjuvant (e.g., incomplete Freund's adjuvant) and immunizing HLA-A2 transgenic mice subcutaneously at multiple sites on day 0, with booster immunizations on days 7 and 14, followed by assessment of CTL responses by tetramer staining or killing assays.
|
| ADME/Pharmacokinetics |
Not available. As a synthetic peptide with TFA salt, pharmacokinetics include rapid absorption following subcutaneous administration, distribution to lymphoid tissues, and degradation by serum and tissue proteases. Half-life is typically minutes to hours depending on formulation and route of administration.
|
| Toxicity/Toxicokinetics |
Not available. The peptide is generally well-tolerated in preclinical immunization studies at typical vaccine doses. The TFA counterion is present at low levels. No significant toxicity has been reported for this specific peptide. It is not intended for systemic administration at high doses.
|
| References |
|
| Additional Infomation |
MART-1 (26-35) TFA is a research-grade peptide widely used as a model antigen in cancer immunology, T-cell epitope mapping, and melanoma vaccine development. It has been evaluated in multiple clinical trials as part of peptide-based cancer vaccines for HLA-A2-positive melanoma patients. The TFA salt enhances solubility and lyophilization properties for laboratory use.
|
| Molecular Formula |
C44H75F3N10O16
|
|---|---|
| Related CAS # |
MART-1 (26-35) (human);156251-01-3
|
| Sequence |
Glu-Ala-Ala-Gly-Ile-Gly-Ile-Leu-Thr-ValEAAGIGILTV
|
| SequenceShortening |
EAAGIGILTV
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~5 mg/mL (~4.73 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (2.36 mM) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Suspended solution; with ultrasonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
